LX1606 (aka LX1032), a Novel Inhibitor of Serotonin Synthesis, Alleviates Development of Inflammatory Bowel Disease in a Preclinical Model


Abstract

LX1606 is a novel, orally-delivered inhibitor of tryptophan hydroxylase that reduces serotonin production. It is absorbed into peripheral circulation and does not cross the blood-brain barrier. LX1606 consistently reduced 5-HT levels in the periphery but not in the brain. Treatment with LX1606 showed a strong positive effect in ameliorating TNBS-induced IBD in mice as assessed by various parameters of disease development. These preclinical data demonstrate that inhibition of TPH activity by LX1606 may provide a new approach for the treatment of IBD and its serotonin-mediated symptoms.
Poster
non-peer-reviewed

LX1606 (aka LX1032), a Novel Inhibitor of Serotonin Synthesis, Alleviates Development of Inflammatory Bowel Disease in a Preclinical Model


Author Information


PDF Share